Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-6-21
pubmed:abstractText
Adverse effects of erythropoietin (EPO) on tumor progression and survival were observed in recent phase 3 oncology trials. However, mechanisms remain poorly understood. We tested the effects of exogenous EPO on murine B16F10 melanoma growth in a subcutaneous tumor transplant model, and for the first time, in a model of spontaneous tumor formation within autochthonous epithelial tissues using murine mammary tumor virus promoter polyoma virus middle T antigen (MMTV-PyMT) transgenic mice. EPO receptor (EPOR) messenger RNA (mRNA) was detectable in both B16F10 tumors and mammary tumors from MMTV-PyMT mice but was 0.12 +/- 0.02% and 1.3 +/- 0.91% of the EPOR mRNA level in murine erythroid HCD-57 cells, respectively. B16F10 tumor growth rates in mice treated for 3 weeks with 30 microg/kg per week of darbepoetin alpha, 0.41 inverse days (range, 0.05-0.69 inverse days; n = 16), were similar to tumor growth rates observed in mice treated with PBS, 0.42 inverse days (range, 0.10-0.69 inverse days; n = 17). In contrast, darbepoetin alpha raised hematocrit levels to 0.593 (maximum, 0.729) compared with 0.448 (maximum, 0.532) in PBS-treated mice (P = .0004). In MMTV-PyMT mice, the weights of tumor-bearing mammary glands in mice treated for 6 weeks with 30 microg/kg per week of darbepoetin alpha, 3.37 g (range, 1.94-5.81 g; n = 27), did not significantly differ from the weights in PBS-treated mice, 3.76 g (range, 2.30-6.33 g; n = 26). In contrast, darbepoetin alpha raised hematocrit levels to 0.441 (maximum, 0.606) compared with 0.405 (maximum, 0.492) in PBS-treated mice (P = .05). Thus, effects of exogenous EPO on tumor growth were not recapitulated in these murine tumor models.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-11250712, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-11259101, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-11414753, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-12807756, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-1312220, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-1420106, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-14463220, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-14575968, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-14578209, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-16087945, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-16698707, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-1705834, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17206489, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17312332, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17579721, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-17582631, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18227526, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18314434, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18676735, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-18714393, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-19040789, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-19410717, http://linkedlifedata.com/resource/pubmed/commentcorrection/20563259-9270023
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:issn
1936-5233
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
176-80
pubmed:year
2010
pubmed:articleTitle
Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.
pubmed:affiliation
Department of Medicine/Hematology and the Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
pubmed:publicationType
Journal Article